P21 10 MG

P21, also known as p21^Cip1/Waf1, is a potent cyclin-dependent kinase (CDK) inhibitor with a central role in regulating the cell cycle. It functions primarily by binding to and inhibiting cyclin-CDK complexes such as cyclin-CDK2, cyclin-CDK1, and cyclin-CDK4/6, thereby controlling cell cycle progression at G1 and S phases and inducing cell cycle arrest in response to DNA damage.

Research involving p21 commonly explores:

• Its molecular mechanism of inhibiting CDKs to halt cell cycle progression, enabling DNA repair or induction of senescence.
• The role of p21 in mediating p53-dependent cell cycle arrest following genotoxic stress, contributing to tumor suppression.
• Interactions with proliferating cell nuclear antigen (PCNA), modulating DNA replication and repair processes.
• Dual functions in both promoting growth arrest and, sometimes, stabilizing CDK complexes depending on its abundance.
• Its regulatory effects on transcription factors and gene expression, including modulation of estrogen receptor activity.
• Therapeutic implications in cancer biology, cell senescence, apoptosis, and aging-related diseases.
P21 is extensively studied as a critical checkpoint protein in cell cycle regulation and a target for cancer therapeutics and regenerative medicine research.
It is generally provided as a recombinant protein or peptide fragment for laboratory research use only (RUO) and is not intended for therapeutic or diagnostic use in humans or animals.

Product details:

• Synonyms: p21, p21^Cip1/Waf1, CDKN1A
• Purity: Research-grade protein or peptide
• Molecular Weight: Approximately 21 kDa (full protein)
• Appearance: Lyophilized powder or solution depending on formulation

This product is intended exclusively for scientific research and laboratory investigation in compliance with regulatory guidelines.